ENHERTU (Trastuzumab Deruxtecan)

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of:

• Adult patients with unresectable or metastatic HER2-positive breast cancer.
• Adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC).
• Adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Note: Enhertu (trastuzumab deruxtecan) is an FDA-approved medication.